Logo Akeso, Inc.
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Employees
3,761
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
98.08CNY
Average target price
150.59CNY
Spread / Average Target
+53.53%

Quarterly revenue - Rate of surprise